Bernhard Resch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Bernhard Resch has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
W Müller
6 shared publicationsE Resch
Medical University of Graz, Graz, Austria
3 shared publicationsU Maurer
Medical University of Graz, Graz, Austria
3 shared publicationsW. Müller
3 shared publicationsA. Radinger
2 shared publications- Alexander Binder
Department of General Paediatrics, Medical University of Graz, Auenbruggerplatz 30, A-8036 Graz, Austria
2 shared publications
Latest Publications
- 17 November 2011
- Published by Georg Thieme Verlag KG in Zeitschrift für Geburtshilfe und Neonatologie
- Vol. 215 (S 01) , PO06_04
Kongenitaler Chylothorax – Eine systematische Untersuchung eigener Fälle und Review der Literatur
Ziel: Aufgrund der Seltenheit des kongenitalen Chylothorax stützen sich aktuelle Empfehlungen lediglich auf einzelne Fallbeschreibungen. Zielsetzung der Studie war es die wichtigsten medizinischen Parameter bezüglich des Krankheitsverlaufs zu beschreiben, mögliche Beeinträchtigungen der Lungenfunktion zu dokumentieren und Therapieempfehlungen zu entwickeln. Methodik: Die Daten aller Kinder, die in den letzten 15 Jahren an der Uniklinik in Graz mit kongenitalem Chylothorax behandelt wurden, wurden retrospektiv ausgewertet. Zusätzlich wurden eine telefonische Befragung der Eltern und eine Lungenfunktionsdiagnostik durchgeführt. Die Literaturrecherche wurde in englisch- und deutschsprachigen, wissenschaftlichen Datenbanken durchgeführt. Einschlusskriterien waren der Nachweis mittels biochemischer Analyse des Ergusses (Lymphozyten-Rate>80% bzw. Nachweis von Chylomikronen) und ein spontanes Auftreten innerhalb der ersten zwei Lebensmonate. Ergebnis: In Graz wurden 6 Kinder mit kongenitalem Chylothorax behandelt. Alle Kinder überlebten. Ein Follow-up war bei allen sechs Kindern möglich und erfolgte im Durchschnitt im Alter von 7 Jahren. In einem Fall wurde die Diagnose eines Noonan-Syndroms, bei einem anderen die eines Autismus gestellt. In der Lungenfunktionsuntersuchung zeigte sich bei 3 Kindern ein grenzwertig pathologischer Befund.Für den Review wurden 361 Fälle berücksichtigt. Eine intrauterine Diagnosestellung erfolgte in 61%, eine intrauterine Intervention in 68% aller Fälle. 75% zeigten bereits bei der Geburt Symptome. Eine MCT-Diät wurde bei 29% und seit 2003 Octreotid in 19% aller Fälle eingesetzt. Eine operative Sanierung wurde bei 14% durchgeführt. Die Mortalitätsrate betrug 26%. Schlussfolgerung: Klinische Studien zu Therapieempfehlungen fehlen. Der Verlauf und die Prognose sind vorwiegend von bestehenden Begleiterkrankungen abhängig. Meist gelingt ein Ausheilen mittels konservativer Therapie. Bei fehlendem Ansprechen sollte vor operativer Intervention eine Therapie mittels Octreotid erfolgen. Literatur: [1] Pisek G. Report of a case of chylothorax. Arch. Pediat. 1917;34:929–932. [2] Stewart C, Linner H. Chylothorax in the newborn infant: report of a case. Am J Dis Child. 1926;31(5):654–656. [3] Defoort P, Thiery M. Antenatal diagnosis of congenital chylothorax by gray scale sonography. J. Clin. Ultrasound. 1978;6(1):47–48. [4] Ergaz Z, Bar-Oz B, Yatsiv I, Arad I. Congenital chylothorax: clinical course and prognostic significance. Pediatr. Pulmonol. 2009 Aug;44(8):806–811. [5] Maayan-Metzger A, Sack J, Mazkereth R, Vardi A, Kuint J. Somatostatin treatment of congenital chylothorax may induce transient hypothyroidism in newborns. Acta Paediatr. 2005 Juni;94(6):785–789. [6] Brodman RF. Congenital chylothorax. Recommendations for treatment. N Y State J Med. 1975März;75(4):553–557. [7] Yancy WS, Spock A. Spontaneous neonatal pleural effusion. J. Pediatr. Surg. 1967 Aug;2(4):313–319. [8] Rocha G, Fernandes P, Rocha P, Quintas C, Martins T, Proença E. Pleural effusions in the neonate. Acta Paediatr. 2006 Juli;95(7):791–798. [9] Caserío S, Gallego C, Martin P, Moral M, Pallás C, Galindo A. Congenital chylothorax: from foetal life to adolescence. Acta Paediatr [Internet]. 2010 Mai 28 [zitiert 2010 Sep 24];Available from:http://www.ncbi.nlm.nih.gov/pubmed/20528795 [10] Tsukimori K, Nakanami N, Fukushima K, Yoshimura T, Hikino S, Nakano H. Pleural fluid/serum immunoglobulin ratio is a diagnostic marker for congenital chylothorax in utero. J Perinat Med. 2006;34(4):313–317. [11] Kallanagowdar C, Craver RD. Neonatal pleural effusion. Spontaneous chylothorax in a newborn with trisomy 21. Arch. Pathol. Lab. Med. 2006 Feb;130(2):e22–23. [12] Chen CP. Fetal therapy and cytogenetic testing: prenatal detection of chromosome aberration during thoracocentesis for congenital chylothorax by karyotyping from pleural effusion fluid and review of the literature. Genet. Couns. 2005;16(3):301–305. [13] Miera O, Mildenberger E, van Baalen A, Fuhr N. [Neonatal chylothorax with trisomy 21]. Z Geburtshilfe Neonatol. 2004 Feb;208(1):29–31. [14] Turan O, Canter B, Ergenekon E, Koç E, Atalay Y. Chylothorax and respiratory distress in a newborn with trisomy 21. Eur. J. Pediatr. 2001 Dez;160(12):744–745. [15] Al-Tawil K, Ahmed G, Al-Hathal M, Al-Jarallah Y, Campbell N. Congenital chylothorax. Am J Perinatol. 2000;17(3):121–126. [16] Puddy V, Lam BC, Tang M, Wong KY, Lam YH, Wong K, u.a. Variable levels of mosaicism for trisomy 21 in a non-immune hydropic infant with chylothorax. Prenat. Diagn. 1999 Aug;19(8):764–766. [17] Yamamoto T, Koeda T, Tamura A, Sawada H, Nagata I, Nagata N, u.a. Congenital chylothorax in a patient with 21 trisomy syndrome. Acta Paediatr Jpn. 1996 Dez;38(6):689–691. [18] Mussat P, Dommergues M, Parat S, Mandelbrot L, de Gamarra E, Dumez Y, u.a. Congenital chylothorax with hydrops: postnatal care and outcome following antenatal diagnosis. Acta Paediatr. 1995 Juli;84(7):749–755. [19] Hamada H, Fujita K, Kubo T, Iwasaki H. Congenital chylothorax in a trisomy 21 newborn. Arch. Gynecol. Obstet. 1992;252(1):55–58. [20] Van Aerde J, Campbell AN, Smyth JA, Lloyd D, Bryan MH. Spontaneous chylothorax in newborns. Am. J. Dis. Child. 1984 Okt;138(10):961–964. [21] Yoss BS, Lipsitz PJ. Chylothorax in two mongoloid infants. Clin. Genet. 1977 Dez;12(6):357–360. [22] Chen CH, Chen TH, Kuo SJ, Chen CP, Lee DJ, Ke YY, u.a. Genetic evaluation and management of fetal chylothorax: review and insights from a case of Noonan syndrome. Lymphology. 2009 Sep;42(3):134–138. [23] Schlüter G, Steckel M, Schiffmann H, Harms K, Viereck V, Emons G, u.a....
- 17 November 2011
- Published by Georg Thieme Verlag KG in Zeitschrift für Geburtshilfe und Neonatologie
- Vol. 215 (S 01) , PO06_04
Kongenitaler Chylothorax – Eine systematische Untersuchung eigener Fälle und Review der Literatur
Ziel: Aufgrund der Seltenheit des kongenitalen Chylothorax stützen sich aktuelle Empfehlungen lediglich auf einzelne Fallbeschreibungen. Zielsetzung der Studie war es die wichtigsten medizinischen Parameter bezüglich des Krankheitsverlaufs zu beschreiben, mögliche Beeinträchtigungen der Lungenfunktion zu dokumentieren und Therapieempfehlungen zu entwickeln. Methodik: Die Daten aller Kinder, die in den letzten 15 Jahren an der Uniklinik in Graz mit kongenitalem Chylothorax behandelt wurden, wurden retrospektiv ausgewertet. Zusätzlich wurden eine telefonische Befragung der Eltern und eine Lungenfunktionsdiagnostik durchgeführt. Die Literaturrecherche wurde in englisch- und deutschsprachigen, wissenschaftlichen Datenbanken durchgeführt. Einschlusskriterien waren der Nachweis mittels biochemischer Analyse des Ergusses (Lymphozyten-Rate>80% bzw. Nachweis von Chylomikronen) und ein spontanes Auftreten innerhalb der ersten zwei Lebensmonate. Ergebnis: In Graz wurden 6 Kinder mit kongenitalem Chylothorax behandelt. Alle Kinder überlebten. Ein Follow-up war bei allen sechs Kindern möglich und erfolgte im Durchschnitt im Alter von 7 Jahren. In einem Fall wurde die Diagnose eines Noonan-Syndroms, bei einem anderen die eines Autismus gestellt. In der Lungenfunktionsuntersuchung zeigte sich bei 3 Kindern ein grenzwertig pathologischer Befund.Für den Review wurden 361 Fälle berücksichtigt. Eine intrauterine Diagnosestellung erfolgte in 61%, eine intrauterine Intervention in 68% aller Fälle. 75% zeigten bereits bei der Geburt Symptome. Eine MCT-Diät wurde bei 29% und seit 2003 Octreotid in 19% aller Fälle eingesetzt. Eine operative Sanierung wurde bei 14% durchgeführt. Die Mortalitätsrate betrug 26%. Schlussfolgerung: Klinische Studien zu Therapieempfehlungen fehlen. Der Verlauf und die Prognose sind vorwiegend von bestehenden Begleiterkrankungen abhängig. Meist gelingt ein Ausheilen mittels konservativer Therapie. Bei fehlendem Ansprechen sollte vor operativer Intervention eine Therapie mittels Octreotid erfolgen. Literatur: [1] Pisek G. Report of a case of chylothorax. Arch. Pediat. 1917;34:929–932. [2] Stewart C, Linner H. Chylothorax in the newborn infant: report of a case. Am J Dis Child. 1926;31(5):654–656. [3] Defoort P, Thiery M. Antenatal diagnosis of congenital chylothorax by gray scale sonography. J. Clin. Ultrasound. 1978;6(1):47–48. [4] Ergaz Z, Bar-Oz B, Yatsiv I, Arad I. Congenital chylothorax: clinical course and prognostic significance. Pediatr. Pulmonol. 2009 Aug;44(8):806–811. [5] Maayan-Metzger A, Sack J, Mazkereth R, Vardi A, Kuint J. Somatostatin treatment of congenital chylothorax may induce transient hypothyroidism in newborns. Acta Paediatr. 2005 Juni;94(6):785–789. [6] Brodman RF. Congenital chylothorax. Recommendations for treatment. N Y State J Med. 1975März;75(4):553–557. [7] Yancy WS, Spock A. Spontaneous neonatal pleural effusion. J. Pediatr. Surg. 1967 Aug;2(4):313–319. [8] Rocha G, Fernandes P, Rocha P, Quintas C, Martins T, Proença E. Pleural effusions in the neonate. Acta Paediatr. 2006 Juli;95(7):791–798. [9] Caserío S, Gallego C, Martin P, Moral M, Pallás C, Galindo A. Congenital chylothorax: from foetal life to adolescence. Acta Paediatr [Internet]. 2010 Mai 28 [zitiert 2010 Sep 24];Available from:http://www.ncbi.nlm.nih.gov/pubmed/20528795 [10] Tsukimori K, Nakanami N, Fukushima K, Yoshimura T, Hikino S, Nakano H. Pleural fluid/serum immunoglobulin ratio is a diagnostic marker for congenital chylothorax in utero. J Perinat Med. 2006;34(4):313–317. [11] Kallanagowdar C, Craver RD. Neonatal pleural effusion. Spontaneous chylothorax in a newborn with trisomy 21. Arch. Pathol. Lab. Med. 2006 Feb;130(2):e22–23. [12] Chen CP. Fetal therapy and cytogenetic testing: prenatal detection of chromosome aberration during thoracocentesis for congenital chylothorax by karyotyping from pleural effusion fluid and review of the literature. Genet. Couns. 2005;16(3):301–305. [13] Miera O, Mildenberger E, van Baalen A, Fuhr N. [Neonatal chylothorax with trisomy 21]. Z Geburtshilfe Neonatol. 2004 Feb;208(1):29–31. [14] Turan O, Canter B, Ergenekon E, Koç E, Atalay Y. Chylothorax and respiratory distress in a newborn with trisomy 21. Eur. J. Pediatr. 2001 Dez;160(12):744–745. [15] Al-Tawil K, Ahmed G, Al-Hathal M, Al-Jarallah Y, Campbell N. Congenital chylothorax. Am J Perinatol. 2000;17(3):121–126. [16] Puddy V, Lam BC, Tang M, Wong KY, Lam YH, Wong K, u.a. Variable levels of mosaicism for trisomy 21 in a non-immune hydropic infant with chylothorax. Prenat. Diagn. 1999 Aug;19(8):764–766. [17] Yamamoto T, Koeda T, Tamura A, Sawada H, Nagata I, Nagata N, u.a. Congenital chylothorax in a patient with 21 trisomy syndrome. Acta Paediatr Jpn. 1996 Dez;38(6):689–691. [18] Mussat P, Dommergues M, Parat S, Mandelbrot L, de Gamarra E, Dumez Y, u.a. Congenital chylothorax with hydrops: postnatal care and outcome following antenatal diagnosis. Acta Paediatr. 1995 Juli;84(7):749–755. [19] Hamada H, Fujita K, Kubo T, Iwasaki H. Congenital chylothorax in a trisomy 21 newborn. Arch. Gynecol. Obstet. 1992;252(1):55–58. [20] Van Aerde J, Campbell AN, Smyth JA, Lloyd D, Bryan MH. Spontaneous chylothorax in newborns. Am. J. Dis. Child. 1984 Okt;138(10):961–964. [21] Yoss BS, Lipsitz PJ. Chylothorax in two mongoloid infants. Clin. Genet. 1977 Dez;12(6):357–360. [22] Chen CH, Chen TH, Kuo SJ, Chen CP, Lee DJ, Ke YY, u.a. Genetic evaluation and management of fetal chylothorax: review and insights from a case of Noonan syndrome. Lymphology. 2009 Sep;42(3):134–138. [23] Schlüter G, Steckel M, Schiffmann H, Harms K, Viereck V, Emons G, u.a....
- 1 November 2011
- Published by Springer Nature in Pediatric Research
- Vol. 70, 203
Early Episodes of Hypocarbia and Early-Onset Sepsis are Risk Factors for Cystic Periventricular Leukomalacia in the Preterm Infant
- 1 November 2011
- Published by Springer Nature in Pediatric Research
- Vol. 70, 203
Early Episodes of Hypocarbia and Early-Onset Sepsis are Risk Factors for Cystic Periventricular Leukomalacia in the Preterm Infant
- 1 November 2011
- Published by Springer Nature in Pediatric Research
- Vol. 70, 204
Preterm Twins and Triplets are at Increased Risk for the Development of Periventricular Leukomalacia
- 1 November 2011
- Published by Springer Nature in Pediatric Research
- Vol. 70, 204
Preterm Twins and Triplets are at Increased Risk for the Development of Periventricular Leukomalacia
- 1 November 2011
- Published by Springer Nature in Pediatric Research
- Vol. 70, 202
Cystic Periventricular Leukomalacia: A Declining Source of Severe Neurodevelopmental Impairment in Preterm Infants?
- 1 November 2011
- Published by Springer Nature in Pediatric Research
- Vol. 70, 202
Cystic Periventricular Leukomalacia: A Declining Source of Severe Neurodevelopmental Impairment in Preterm Infants?
- 13 November 2006
- Published by Georg Thieme Verlag KG in Zeitschrift für Geburtshilfe und Neonatologie
- Vol. 210 (S 5) , P7
Association between IL-6–174 (G/C) polymorphism and cystic periventricular leukomalacia in preterm infants
Background: The fetal inflammatory response syndrome plays a central role in the pathogenesis of white matter damage, i.e. cystic periventricular leukomalacia (PVL) in the preterm infant. High levels of proinflammatory cytokines including interleukin-6 (IL-6) have been observed in autopsies of brains of these infants. Thus, an association between IL-6–174 (G/C) polymorphism, affecting IL-6 transcription rate and plasma cytokine levels, and development of PVL might be hypothesized. Patients and methods: The study group (cases) compromised infants with diagnosis of cystic PVL out of a single centre cohort from 1988 to 2005 and their parents. The control group (controls) included healthy newborns born between April and June 2002. Analysis of IL-6–174 (G/C) polymorphisms was performed in cases and their parents from venous blood samples after parental informed consent and in controls from umbilical cord blood samples. Samples were stored at -200 degree Celsius. IL-6 genotyping was performed using a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique. The study was approved by the local ethic committee. Results: Fifty-two cases (and 44 mothers) were enrolled and compared to 395 controls. Rates of homozygous carrier of the IL-6–176C mutation were 17,3% in the cases, 15,9% in their mothers and 14,7% in the controls (differences not significant). Again no differences were found in the subgroup of cases with history of premature rupture of the membranes (PROM) or chorioamnionitis. An increased rate was found in mothers of cases with history of chorioamnionitis (7/23, 30,4%; p=0,0192). Conclusion: We found a significant increased rate of homozygous carriers of the IL-6–176C mutation in mothers with chorioamnionitis and preterm birth with subsequent development of cystic PVL. In case of preterm PROM knowledge of this polymorphism might influence timing of delivery.
- 13 November 2006
- Published by Georg Thieme Verlag KG in Zeitschrift für Geburtshilfe und Neonatologie
- Vol. 210 (S 5) , P7
Association between IL-6–174 (G/C) polymorphism and cystic periventricular leukomalacia in preterm infants
Background: The fetal inflammatory response syndrome plays a central role in the pathogenesis of white matter damage, i.e. cystic periventricular leukomalacia (PVL) in the preterm infant. High levels of proinflammatory cytokines including interleukin-6 (IL-6) have been observed in autopsies of brains of these infants. Thus, an association between IL-6–174 (G/C) polymorphism, affecting IL-6 transcription rate and plasma cytokine levels, and development of PVL might be hypothesized. Patients and methods: The study group (cases) compromised infants with diagnosis of cystic PVL out of a single centre cohort from 1988 to 2005 and their parents. The control group (controls) included healthy newborns born between April and June 2002. Analysis of IL-6–174 (G/C) polymorphisms was performed in cases and their parents from venous blood samples after parental informed consent and in controls from umbilical cord blood samples. Samples were stored at -200 degree Celsius. IL-6 genotyping was performed using a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique. The study was approved by the local ethic committee. Results: Fifty-two cases (and 44 mothers) were enrolled and compared to 395 controls. Rates of homozygous carrier of the IL-6–176C mutation were 17,3% in the cases, 15,9% in their mothers and 14,7% in the controls (differences not significant). Again no differences were found in the subgroup of cases with history of premature rupture of the membranes (PROM) or chorioamnionitis. An increased rate was found in mothers of cases with history of chorioamnionitis (7/23, 30,4%; p=0,0192). Conclusion: We found a significant increased rate of homozygous carriers of the IL-6–176C mutation in mothers with chorioamnionitis and preterm birth with subsequent development of cystic PVL. In case of preterm PROM knowledge of this polymorphism might influence timing of delivery.
- 13 November 2006
- Published by Georg Thieme Verlag KG in Neuropediatrics
- Vol. 210 (S 5) , P7
Association between IL-6-174 (G/C) polymorphism and cystic periventricular leukomalacia in preterm infants
Background: The fetal inflammatory response syndrome plays a central role in the pathogenesis of white matter damage, i.e. cystic periventricular leukomalacia (PVL) in the preterm infant. High levels of proinflammatory cytokines including interleukin-6 (IL-6) have been observed in autopsies of brains of these infants. Thus, an association between IL-6–174 (G/C) polymorphism, affecting IL-6 transcription rate and plasma cytokine levels, and development of PVL might be hypothesized. Patients and methods: The study group (cases) compromised infants with diagnosis of cystic PVL out of a single centre cohort from 1988 to 2005 and their parents. The control group (controls) included healthy newborns born between April and June 2002. Analysis of IL-6–174 (G/C) polymorphisms was performed in cases and their parents from venous blood samples after parental informed consent and in controls from umbilical cord blood samples. Samples were stored at -200 degree Celsius. IL-6 genotyping was performed using a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique. The study was approved by the local ethic committee. Results: Fifty-two cases (and 44 mothers) were enrolled and compared to 395 controls. Rates of homozygous carrier of the IL-6–176C mutation were 17,3% in the cases, 15,9% in their mothers and 14,7% in the controls (differences not significant). Again no differences were found in the subgroup of cases with history of premature rupture of the membranes (PROM) or chorioamnionitis. An increased rate was found in mothers of cases with history of chorioamnionitis (7/23, 30,4%; p=0,0192). Conclusion: We found a significant increased rate of homozygous carriers of the IL-6–176C mutation in mothers with chorioamnionitis and preterm birth with subsequent development of cystic PVL. In case of preterm PROM knowledge of this polymorphism might influence timing of delivery.
- 13 November 2006
- Published by Georg Thieme Verlag KG in Neuropediatrics
- Vol. 210 (S 5) , P7
Association between IL-6-174 (G/C) polymorphism and cystic periventricular leukomalacia in preterm infants
Background: The fetal inflammatory response syndrome plays a central role in the pathogenesis of white matter damage, i.e. cystic periventricular leukomalacia (PVL) in the preterm infant. High levels of proinflammatory cytokines including interleukin-6 (IL-6) have been observed in autopsies of brains of these infants. Thus, an association between IL-6–174 (G/C) polymorphism, affecting IL-6 transcription rate and plasma cytokine levels, and development of PVL might be hypothesized. Patients and methods: The study group (cases) compromised infants with diagnosis of cystic PVL out of a single centre cohort from 1988 to 2005 and their parents. The control group (controls) included healthy newborns born between April and June 2002. Analysis of IL-6–174 (G/C) polymorphisms was performed in cases and their parents from venous blood samples after parental informed consent and in controls from umbilical cord blood samples. Samples were stored at -200 degree Celsius. IL-6 genotyping was performed using a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique. The study was approved by the local ethic committee. Results: Fifty-two cases (and 44 mothers) were enrolled and compared to 395 controls. Rates of homozygous carrier of the IL-6–176C mutation were 17,3% in the cases, 15,9% in their mothers and 14,7% in the controls (differences not significant). Again no differences were found in the subgroup of cases with history of premature rupture of the membranes (PROM) or chorioamnionitis. An increased rate was found in mothers of cases with history of chorioamnionitis (7/23, 30,4%; p=0,0192). Conclusion: We found a significant increased rate of homozygous carriers of the IL-6–176C mutation in mothers with chorioamnionitis and preterm birth with subsequent development of cystic PVL. In case of preterm PROM knowledge of this polymorphism might influence timing of delivery.
- 1 May 2006
- Published by Elsevier in Value in Health
- Vol. 9 (3) , A94
PRS8 THE COST-EFFECTIVENESS OF PALIVIZUMAB IN AUSTRIA
- 1 May 2006
- Published by Elsevier in Value in Health
- Vol. 9 (3) , A94
PRS8 THE COST-EFFECTIVENESS OF PALIVIZUMAB IN AUSTRIA
- 30 September 2003
- Published by Georg Thieme Verlag KG in Klinische Padiatrie
- Vol. 215 (5) , 257-261
Inhalative Therapie mit Stickstoffmonoxid bei pulmonaler Hypertension: Vergleich des Effektes bei Früh- und Neugeborenen
Background: Inhaled nitric oxide (iNO) is used as a vasodilator in pulmonary hypertension (PH) of the newborn infant. Patients and Methods: Retrospective analysis of patients, who were treated at our department with iNO in the period from 1994-2001. Response was defined as an increase of the paO2/FiO2 Ratio ≥ 20 % and/or a decrease of the oxygenation index (OI) ≥ 20 % after 2 h (early response), and consecutively after 24 h (late response). The patients were divided into a) primary persistent pulmonary hypertension of the newbom (PPHN), or b) pulmonary hypertension secondary to meconium aspiration syndrome (MAS), sepsis or congenital diaphragmatic hernia (CDH). Results: Between 1994 and 2001 we treated 47 patients with iNO at our neonatal intensive care unit. We included 16 (35 %) preterm infants (GA 34,5 [25 - 37] weeks, GG 2061 [680 - 3410] g) (Median/Range) and 31 (65 %) newbom (GA 40 [38 - 42] weeks, GG 3510 [2550 - 4560] g). 18 (38 %) patients suffered from primary PPHN, 29 (62 %) from secondary PPHN (14 MAS [30 %], 8 sepsis [17 %], 4 CDH [8 %]). 8 (50 %) preterm and 20 (64 %) term infants showed a positive iNO response after 2 h, again 8 (50 %) preterm and 20 (64%) term infants showed a positive iNO response after 24 h. There was neither a significant difference between term and preterm infants at 2 h, nor at 24 h. Between 2 h and 24 h 10 patients changed in their response to iNO. 5 (18 %) patients with early response showed a significant degradation after 24 h, whereas 5 (26 %) of the patients without early response showed a significant improvement of the oxygenation alter 24 h. Alltogether 13 (72 %) patients with PPHN, 8 (57 %) with MAS, 2 (50 %) with CDH, 4 (50 %) with sepsis showed a positive iNO response after 24 h. In regard to the oxygenation parameters at start of iNO-therapy, the patients with early response did not differ from the patient without response (median OI: 20,0 versus 21,8, median paO2/FiO2 Ratio: 59,3 versus 55,0 mmHg at the start of the iNO therapy). Conclusion: In regard to iNO response, there was no significant difference between term and preterm infants. Due to the changing response, a positive iNO-response after 2 h had no predictive value for the further prognosis of the oxygenation situation under iNO therapy. Hintergrund: Inhalatives Stickstoffmonoxid (iNO) wird als Vasodilatator bei pulmonaler Hypertonie (PH) des Neugeborenen eingesetzt. Patienten und Methodik: Retrospektive Analyse von Patienten, welche im Zeitraum 1994 - 2001 an unserer Abteilung mit iNO betreut wurden. Ein Ansprechen wurde als Zunahme der paO2/FiO2 Ratio ≥ 20 % und/oder Abfall des Oxygenierungsindexes (OI) ≥ 20 % nach 2 h (positiver 2 h-Effekt) und nach 24 h (positiver 24 h Effekt) definiert. Die Patienten wurden anhand ihrer Grunderkrankungen in a) primären pulmonalen Hochdruck (PPHN) oder b) sekundären pulmonalen Hochdruck (PH bei Mekonium-Aspirations-Syndrom [MAS], Sepsis und Zwerchfellhernie [CDH]) unterteilt. Ergebnisse: Zwischen 1994 und 2001 wurden auf unserer neonatologischen Intensivstation 47 Kinder mit iNO behandelt. Davon waren 16 (35 %) Frühgeborene (GA 34,5 [25 - 37] Wochen, GG 2061 [680 - 3410] g) (Median/Range) und 31 (65 %) Neugeborene (GA 40 [38 - 42] Wochen, GG 3510 [2550 - 4560] g). 18 (38 %) Patienten litten an einem primären PPHN, 29 (62 %) an einem sekundären pulmonalen Hochdruck (14 MAS [30 %], 8 an einer Sepsis [17 %], 4 CDH [8 %]). Insgesamt reagierten 8 (50 %) Früh- und 20 (64 %) Neugeborene nach 2 Stunden, beziehungsweise 8 (50 %) Früh- und 20 (64 %) Neugeborene nach 24 Stunden positiv auf die iNO-Therapie. Es zeigte sich kein Unterschied im Ansprechen auf iNO zwischen Früh- und Neugeborenen. Zwischen den Analysezeitpunkten 2 h und 24 h wechselten jedoch 10 Patienten den Reaktionstyp. 5 (18 %) Patienten mit positivem 2 h-Effekt zeigten nach 24 h eine signifikante Verschlechterung, wohingegen 5 (26 %) der Patienten ohne 2 h-Effekt nach 24 h eine signifikante Verbesserung der Oxygenierung zeigten. Nach der Grunderkrankung aufgegliedert, zeigten insgesamt 13 (72 %) Patienten mit PPHN, 8 (57 %) mit MAS, 2 (50 %) mit CDH, 4 (50 %) mit Sepsis einen positiven 24 h-Effekt. In Bezug auf die Oxygenierungsparameter am Start der iNO-Therapie unterschieden sich die Patienten mit positiven 2 h-Effekt nicht von den Patienten ohne 2 h-Effekt (medianer OI: 20,0 versus 21,8, medianer paO2/FiO2O Ratio: 59,3 versus 55,0 mmHg). Schlussfolgerung: Im Ansprechen auf iNO zeigte sich kein Unterschied zwischen Früh- und Neugeborenen. Aufgrund des wechselnden iNO-Effektes war ein positiver 2 h-Effekt kein sicherer Ausgangspunkt für die weitere Prognose der Oxygenierungssituation unter iNO-Therapie.
- 30 September 2003
- Published by Georg Thieme Verlag KG in Klinische Padiatrie
- Vol. 215 (5) , 257-261
Inhalative Therapie mit Stickstoffmonoxid bei pulmonaler Hypertension: Vergleich des Effektes bei Früh- und Neugeborenen
Background: Inhaled nitric oxide (iNO) is used as a vasodilator in pulmonary hypertension (PH) of the newborn infant. Patients and Methods: Retrospective analysis of patients, who were treated at our department with iNO in the period from 1994-2001. Response was defined as an increase of the paO2/FiO2 Ratio ≥ 20 % and/or a decrease of the oxygenation index (OI) ≥ 20 % after 2 h (early response), and consecutively after 24 h (late response). The patients were divided into a) primary persistent pulmonary hypertension of the newbom (PPHN), or b) pulmonary hypertension secondary to meconium aspiration syndrome (MAS), sepsis or congenital diaphragmatic hernia (CDH). Results: Between 1994 and 2001 we treated 47 patients with iNO at our neonatal intensive care unit. We included 16 (35 %) preterm infants (GA 34,5 [25 - 37] weeks, GG 2061 [680 - 3410] g) (Median/Range) and 31 (65 %) newbom (GA 40 [38 - 42] weeks, GG 3510 [2550 - 4560] g). 18 (38 %) patients suffered from primary PPHN, 29 (62 %) from secondary PPHN (14 MAS [30 %], 8 sepsis [17 %], 4 CDH [8 %]). 8 (50 %) preterm and 20 (64 %) term infants showed a positive iNO response after 2 h, again 8 (50 %) preterm and 20 (64%) term infants showed a positive iNO response after 24 h. There was neither a significant difference between term and preterm infants at 2 h, nor at 24 h. Between 2 h and 24 h 10 patients changed in their response to iNO. 5 (18 %) patients with early response showed a significant degradation after 24 h, whereas 5 (26 %) of the patients without early response showed a significant improvement of the oxygenation alter 24 h. Alltogether 13 (72 %) patients with PPHN, 8 (57 %) with MAS, 2 (50 %) with CDH, 4 (50 %) with sepsis showed a positive iNO response after 24 h. In regard to the oxygenation parameters at start of iNO-therapy, the patients with early response did not differ from the patient without response (median OI: 20,0 versus 21,8, median paO2/FiO2 Ratio: 59,3 versus 55,0 mmHg at the start of the iNO therapy). Conclusion: In regard to iNO response, there was no significant difference between term and preterm infants. Due to the changing response, a positive iNO-response after 2 h had no predictive value for the further prognosis of the oxygenation situation under iNO therapy. Hintergrund: Inhalatives Stickstoffmonoxid (iNO) wird als Vasodilatator bei pulmonaler Hypertonie (PH) des Neugeborenen eingesetzt. Patienten und Methodik: Retrospektive Analyse von Patienten, welche im Zeitraum 1994 - 2001 an unserer Abteilung mit iNO betreut wurden. Ein Ansprechen wurde als Zunahme der paO2/FiO2 Ratio ≥ 20 % und/oder Abfall des Oxygenierungsindexes (OI) ≥ 20 % nach 2 h (positiver 2 h-Effekt) und nach 24 h (positiver 24 h Effekt) definiert. Die Patienten wurden anhand ihrer Grunderkrankungen in a) primären pulmonalen Hochdruck (PPHN) oder b) sekundären pulmonalen Hochdruck (PH bei Mekonium-Aspirations-Syndrom [MAS], Sepsis und Zwerchfellhernie [CDH]) unterteilt. Ergebnisse: Zwischen 1994 und 2001 wurden auf unserer neonatologischen Intensivstation 47 Kinder mit iNO behandelt. Davon waren 16 (35 %) Frühgeborene (GA 34,5 [25 - 37] Wochen, GG 2061 [680 - 3410] g) (Median/Range) und 31 (65 %) Neugeborene (GA 40 [38 - 42] Wochen, GG 3510 [2550 - 4560] g). 18 (38 %) Patienten litten an einem primären PPHN, 29 (62 %) an einem sekundären pulmonalen Hochdruck (14 MAS [30 %], 8 an einer Sepsis [17 %], 4 CDH [8 %]). Insgesamt reagierten 8 (50 %) Früh- und 20 (64 %) Neugeborene nach 2 Stunden, beziehungsweise 8 (50 %) Früh- und 20 (64 %) Neugeborene nach 24 Stunden positiv auf die iNO-Therapie. Es zeigte sich kein Unterschied im Ansprechen auf iNO zwischen Früh- und Neugeborenen. Zwischen den Analysezeitpunkten 2 h und 24 h wechselten jedoch 10 Patienten den Reaktionstyp. 5 (18 %) Patienten mit positivem 2 h-Effekt zeigten nach 24 h eine signifikante Verschlechterung, wohingegen 5 (26 %) der Patienten ohne 2 h-Effekt nach 24 h eine signifikante Verbesserung der Oxygenierung zeigten. Nach der Grunderkrankung aufgegliedert, zeigten insgesamt 13 (72 %) Patienten mit PPHN, 8 (57 %) mit MAS, 2 (50 %) mit CDH, 4 (50 %) mit Sepsis einen positiven 24 h-Effekt. In Bezug auf die Oxygenierungsparameter am Start der iNO-Therapie unterschieden sich die Patienten mit positiven 2 h-Effekt nicht von den Patienten ohne 2 h-Effekt (medianer OI: 20,0 versus 21,8, medianer paO2/FiO2O Ratio: 59,3 versus 55,0 mmHg). Schlussfolgerung: Im Ansprechen auf iNO zeigte sich kein Unterschied zwischen Früh- und Neugeborenen. Aufgrund des wechselnden iNO-Effektes war ein positiver 2 h-Effekt kein sicherer Ausgangspunkt für die weitere Prognose der Oxygenierungssituation unter iNO-Therapie.
- 1 February 2003
- Published by Wiley in Acta Paediatrica
- Vol. 92 (2) , 243-245
Procalcitonin and interleukin‐6 in the diagnosis of early‐onset sepsis of the neonate
The reliability of procalcitonin (PCT) and interleukin‐6 (IL‐6) was determined and compared with that of C‐reactive protein (CRP) in the diagnosis of early‐onset sepsis of the neonate within the first 12 h of life. ROC analysis of values of 41 neonates with blood‐cultures‐positive and clinical sepsis compared with those of 27 uninfected neonates revealed sensitivities for PCT (≥6ng/mL), IL‐6 (≥60pg/mL), and CRP (≥2.5 mg/L) of 77%, 54%, and 69% and specificities of 91%, 100% and 96%, respectively. Sensitivity of CRP at ≥8 mg/L was 49% (p= 0.012 compared to PCT). Conclusion: PCT was the most sensitive diagnostic parameter in the diagnosis of early‐onset sepsis within 12 h of life.
- 1 February 2003
- Published by Wiley in Acta Paediatrica
- Vol. 92 (2) , 243-245
Procalcitonin and interleukin‐6 in the diagnosis of early‐onset sepsis of the neonate
The reliability of procalcitonin (PCT) and interleukin‐6 (IL‐6) was determined and compared with that of C‐reactive protein (CRP) in the diagnosis of early‐onset sepsis of the neonate within the first 12 h of life. ROC analysis of values of 41 neonates with blood‐cultures‐positive and clinical sepsis compared with those of 27 uninfected neonates revealed sensitivities for PCT (≥6ng/mL), IL‐6 (≥60pg/mL), and CRP (≥2.5 mg/L) of 77%, 54%, and 69% and specificities of 91%, 100% and 96%, respectively. Sensitivity of CRP at ≥8 mg/L was 49% (p= 0.012 compared to PCT). Conclusion: PCT was the most sensitive diagnostic parameter in the diagnosis of early‐onset sepsis within 12 h of life.
- 3 May 2002
- Published by Wiley in Pediatric Pulmonology
- Vol. 33 (6) , 501-504
Pulmonary eosinophilic vasculitis in a neonate with congenital chylothorax*
We report a case of congenital bilateral chylothorax, complicated by pulmonary eosinophilic vasculitis and transient eosinophilia. Excluding all known forms of eosinophilic pulmonary disease either histologically or clinically, possible mechanisms of its etiology are discussed. Treatment with corticosteroids was successful, and after a prolonged clinical course the patient recovered by age 2 years.
- 3 May 2002
- Published by Wiley in Pediatric Pulmonology
- Vol. 33 (6) , 501-504
Pulmonary eosinophilic vasculitis in a neonate with congenital chylothorax*
We report a case of congenital bilateral chylothorax, complicated by pulmonary eosinophilic vasculitis and transient eosinophilia. Excluding all known forms of eosinophilic pulmonary disease either histologically or clinically, possible mechanisms of its etiology are discussed. Treatment with corticosteroids was successful, and after a prolonged clinical course the patient recovered by age 2 years.